Atlas Trials

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Clinical trial NCT06517511 · RECRUITING

Trial details

NCT number
NCT06517511
Sponsor
Sun Yat-sen University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2024-08-01
Primary completion
2027-01-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.